c-Met/HGFR
Les inhibiteurs de c-Met/HGFR ciblent le Récepteur du Facteur de Croissance des Hépatocytes (c-Met), une tyrosine kinase impliquée dans des processus cellulaires tels que la croissance, la motilité et la morphogenèse. La signalisation de c-Met est impliquée dans la progression du cancer, la métastase et la résistance aux thérapies. Inhiber c-Met peut perturber la croissance et la propagation des tumeurs, faisant de ces inhibiteurs des outils précieux dans la recherche sur le cancer. Chez CymitQuimica, nous proposons des inhibiteurs de c-Met/HGFR pour soutenir vos recherches en oncologie, métastase et thérapies ciblées contre le cancer.
128 produits trouvés pour "c-Met/HGFR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pamufetinib
CAS :<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Formule :C27H23FN4O4SDegré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :518.56Onartuzumab
CAS :<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Degré de pureté :97.3%Couleur et forme :LiquidMasse moléculaire :146.99 kDaJNJ-38877618
CAS :<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Formule :C20H12F2N6Degré de pureté :98.84% - 99.74%Couleur et forme :SolidMasse moléculaire :374.35Rilotumumab
CAS :<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Degré de pureté :SDS-PAGE:95% SEC-HPLC:97.51%Couleur et forme :LiquidMasse moléculaire :145.2 kDaBozitinib
CAS :<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Formule :C20H15F3N8Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :424.38c-Met inhibitor 1
CAS :<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Formule :C17H14N8SDegré de pureté :98.77%Couleur et forme :SolidMasse moléculaire :362.41Emibetuzumab
CAS :<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Degré de pureté :SDS-PAGE:96.2%;SEC-HPLC:98.8%Couleur et forme :LiquidMasse moléculaire :143.74 kDaCSF1R-IN-2
CAS :<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Formule :C20H20FN7O2Degré de pureté :99.29%Couleur et forme :SolidMasse moléculaire :409.42Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Couleur et forme :Odour LiquidPROTAC c-Met degrader-1
CAS :<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Formule :C45H41FN10O5Couleur et forme :SolidMasse moléculaire :820.87c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Formule :C16H13N7OMasse moléculaire :319.11816PF-04217903 phenolsulfonate
CAS :<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Formule :C25H22N8O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :546.56Norleual
CAS :<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Formule :C41H58N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :774.95LMTK3-IN-1
CAS :<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Formule :C18H11F3N4ODegré de pureté :99.89%Couleur et forme :SoildMasse moléculaire :356.3BMS-777607
CAS :<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Formule :C25H19ClF2N4O4Degré de pureté :98.16% - 98.56%Couleur et forme :SolidMasse moléculaire :512.89Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Formule :C29H49N4O10PDegré de pureté :98.01%Couleur et forme :SolidMasse moléculaire :644.69PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Formule :C51H54N10O7Couleur et forme :SolidMasse moléculaire :919.037SU 5616
CAS :<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Formule :C13H8ClNOSDegré de pureté :98.84%Couleur et forme :SoildMasse moléculaire :261.73C-Met inhibitor D9
CAS :<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Formule :C17H15N3O2Degré de pureté :97%Couleur et forme :SolidMasse moléculaire :293.32Telisotuzumab
CAS :<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Degré de pureté :SDS-PAGE:96.4%;SEC-HPLC:98.5%Couleur et forme :LiquidMasse moléculaire :145.50 kDa
